Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HENRY MARK KUERER and ISABELLE BEDROSIAN.
HENRY MARK KUERER
Connection Strength
3.520
ISABELLE BEDROSIAN
  1. Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. J Cancer. 2023; 14(2):193-199.
    View in: PubMed
    Score: 0.220
  2. DCIS and axillary nodal evaluation: compliance with national guidelines. BMC Surg. 2017 Feb 07; 17(1):12.
    View in: PubMed
    Score: 0.146
  3. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8.
    View in: PubMed
    Score: 0.136
  4. Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer. JAMA Surg. 2015 Aug; 150(8):778-86.
    View in: PubMed
    Score: 0.131
  5. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.115
  6. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
    View in: PubMed
    Score: 0.105
  7. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
    View in: PubMed
    Score: 0.105
  8. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
    View in: PubMed
    Score: 0.104
  9. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8.
    View in: PubMed
    Score: 0.092
  10. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
    View in: PubMed
    Score: 0.091
  11. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg. 2009 Sep; 198(3):387-91.
    View in: PubMed
    Score: 0.085
  12. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer. 2009 Apr 01; 115(7):1555-62.
    View in: PubMed
    Score: 0.085
  13. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer. 2007 Dec 01; 110(11):2542-50.
    View in: PubMed
    Score: 0.077
  14. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 01; 107(7):1440-7.
    View in: PubMed
    Score: 0.071
  15. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3):464-70.
    View in: PubMed
    Score: 0.071
  16. Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2024 Oct 23.
    View in: PubMed
    Score: 0.062
  17. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 Nov; 10(9):1025-30.
    View in: PubMed
    Score: 0.058
  18. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023 Dec; 30(13):8327-8334.
    View in: PubMed
    Score: 0.058
  19. Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. J Surg Oncol. 2021 Dec; 124(7):989-994.
    View in: PubMed
    Score: 0.050
  20. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621.
    View in: PubMed
    Score: 0.049
  21. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
    View in: PubMed
    Score: 0.048
  22. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
    View in: PubMed
    Score: 0.048
  23. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Ann Surg Oncol. 2020 Nov; 27(12):4603-4612.
    View in: PubMed
    Score: 0.046
  24. Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Ann Surg Oncol. 2020 Mar; 27(3):730-735.
    View in: PubMed
    Score: 0.044
  25. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat. 2019 Jul; 176(2):435-444.
    View in: PubMed
    Score: 0.043
  26. Surgeon perception versus reality: Opioid use after breast cancer surgery. J Surg Oncol. 2019 Jun; 119(7):909-915.
    View in: PubMed
    Score: 0.042
  27. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol. 2019 Mar; 26(3):815-820.
    View in: PubMed
    Score: 0.042
  28. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol. 2018 Oct; 25(10):2932-2938.
    View in: PubMed
    Score: 0.040
  29. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018 06; 7(6):2718-2726.
    View in: PubMed
    Score: 0.040
  30. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281.
    View in: PubMed
    Score: 0.038
  31. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017 Oct; 24(10):2925-2934.
    View in: PubMed
    Score: 0.038
  32. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34.
    View in: PubMed
    Score: 0.037
  33. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer. 2017 Jul 15; 123(14):2618-2625.
    View in: PubMed
    Score: 0.037
  34. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659.
    View in: PubMed
    Score: 0.036
  35. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol. 2016 10; 23(10):3190-8.
    View in: PubMed
    Score: 0.035
  36. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast?Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25.
    View in: PubMed
    Score: 0.034
  37. Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. Ann Surg. 2016 Jan; 263(1):178-83.
    View in: PubMed
    Score: 0.034
  38. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol. 2016 Mar; 23(3):749-56.
    View in: PubMed
    Score: 0.033
  39. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9.
    View in: PubMed
    Score: 0.032
  40. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):325-33.
    View in: PubMed
    Score: 0.031
  41. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7.
    View in: PubMed
    Score: 0.030
  42. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73.
    View in: PubMed
    Score: 0.030
  43. Timing of infectious complications following breast-conserving therapy with catheter-based accelerated partial breast irradiation. Ann Surg Oncol. 2014 Aug; 21(8):2512-6.
    View in: PubMed
    Score: 0.030
  44. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
    View in: PubMed
    Score: 0.030
  45. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28.
    View in: PubMed
    Score: 0.030
  46. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9.
    View in: PubMed
    Score: 0.028
  47. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol. 2013 Jun; 20(6):1893-9.
    View in: PubMed
    Score: 0.028
  48. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13.
    View in: PubMed
    Score: 0.027
  49. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012 Oct; 19(10):3177-84.
    View in: PubMed
    Score: 0.027
  50. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012 Jul; 13(7):688-95.
    View in: PubMed
    Score: 0.026
  51. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20; 30(6):600-7.
    View in: PubMed
    Score: 0.026
  52. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012 Apr; 19(4):1137-44.
    View in: PubMed
    Score: 0.025
  53. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
    View in: PubMed
    Score: 0.025
  54. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
    View in: PubMed
    Score: 0.025
  55. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24.
    View in: PubMed
    Score: 0.025
  56. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer. 2012 Jan 15; 118(2):342-8.
    View in: PubMed
    Score: 0.025
  57. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
    View in: PubMed
    Score: 0.024
  58. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010 Oct; 17 Suppl 3:280-5.
    View in: PubMed
    Score: 0.023
  59. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:343-51.
    View in: PubMed
    Score: 0.023
  60. The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol. 2011 Sep; 79(3):315-20.
    View in: PubMed
    Score: 0.023
  61. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
    View in: PubMed
    Score: 0.023
  62. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010 Dec; 17(12):3252-8.
    View in: PubMed
    Score: 0.023
  63. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 Oct; 250(4):558-66.
    View in: PubMed
    Score: 0.022
  64. False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden. Breast J. 2009 Nov-Dec; 15(6):645-8.
    View in: PubMed
    Score: 0.022
  65. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg. 2009 Nov; 198(5):720-5.
    View in: PubMed
    Score: 0.021
  66. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 01; 115(5):962-71.
    View in: PubMed
    Score: 0.021
  67. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008 Jul; 196(1):81-7.
    View in: PubMed
    Score: 0.020
  68. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol. 2008 May 20; 26(15):2482-8.
    View in: PubMed
    Score: 0.020
  69. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol. 2008 Jun; 15(6):1696-702.
    View in: PubMed
    Score: 0.020
  70. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31.
    View in: PubMed
    Score: 0.019
  71. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg. 2006 Oct; 192(4):541-4.
    View in: PubMed
    Score: 0.018
  72. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg. 2006 Oct; 192(4):552-5.
    View in: PubMed
    Score: 0.018
  73. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct; 203(4):475-80.
    View in: PubMed
    Score: 0.018
  74. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer. 2006 Aug; 7(3):248-53.
    View in: PubMed
    Score: 0.018
  75. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 01; 104(3):479-90.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.